Cocrystal Pharma, Inc. Common Stock
$1.21
$0.07 (+6.14%)
$1.14Day Range$1.25
Key Statistics
Market Cap
$23.31M
Shares Outstanding
19.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 1, 2008
Round Lot
100
Locale
US
Trading Data
Day Open
$1.14
Day High
$1.25
Day Low
$1.14
Volume
176.5K
VWAP
$1.21
Prev Close
$1.14
Transactions
--
Acc. Volume
--
About Cocrystal Pharma, Inc. Common Stock
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
PHARMACEUTICAL PREPARATIONSSIC 283410 employees19805 N. CREEK PARKWAY, BOTHELL, WA, 98011(786) 459-1831IPO Apr 1, 2008US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001412486
- Composite FIGI
- BBG000V27360
- Share Class FIGI
- BBG001T107W2
- Ticker Root
- COCP
- SIC Code
- 2834
About Cocrystal Pharma, Inc. Common Stock (COCP) Stock
Cocrystal Pharma, Inc. Common Stock (COCP) closed the 2026-09-18 session at $1.21, up 6.14% versus the previous close (+0.07). The stock opened at $1.14 and traded between $1.14 and $1.25 during that session. Session trading volume was 176K shares. The volume-weighted average price (VWAP) is $1.21.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
Cocrystal Pharma, Inc. Common Stock has a market capitalization of $23.3 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. COCP is listed on the XNAS exchange. The company employs approximately 10 people. Cocrystal Pharma, Inc. Common Stock is headquartered in BOTHELL, WA. The recorded listing date is 2008-04-01.
On this page you can find market COCP stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.